Generic dossier
Apremilast
10, 20, 30 mg · Oral suspension · Immunomodulator
Product data
- Strength
- 10, 20, 30 mg
- Dosage form
- Oral suspension
- Dosage-form group
- Oral liquid
- Therapeutic area
- Immunomodulator
- Market
- EU/US
- Status
- Dossier target · Jul 2027
- Development status
- Charged for stability
- Portfolio
- Generic dossier
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23